Ranbaxy Approved for Generic Antara

Ranbaxy Laboratories announced that it has received approval from the Food and Drug Administration (FDA) for manufacturing and marketing of Fenofibrate Capsules, the generic equivalent of Lupin's Antara.

Antara is a fibrate indicated as an adjunct to diet when response to nondrug therapy is inadequate in hypertriglyceridemia (Types IV and V), to reduce elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, in primary hypercholesterolemia and mixed dyslipidemia (Type IIa and IIb).

RELATED: Dyslipidemia Drug Indications

Fenofibrate Capsules will be available in 43mg and 130mg strengths.

For more information call (800) 406-7984 or visit Ranbaxy.com.